🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Mereo BioPharma Group PLC ADR (MREO)

NASDAQ
Currency in USD
3.810
-0.240(-5.93%)
Closed
After Hours
3.790-0.020(-0.525%)
MREO Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
3.7804.140
52 wk Range
1.8605.020
Prev. Close
4.05
Open
4.05
Day's Range
3.78-4.14
52 wk Range
1.86-5.02
Volume
1,442,740
Average Vol. (3m)
755,501
1-Year Change
73.18%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
MREO Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
5.578
Upside
+46.404%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
Show more

Mereo BioPharma Group PLC ADR Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

InvestingPro Research for Mereo BioPharma Group PLC ADR


Market Potential
Explore Mereo's position in the $1B+ osteogenesis imperfecta market, with no approved targeted therapies in the EU, presenting significant growth opportunities
Catalysts Ahead
Key milestones include Phase 2 OI data in H2 2024, Phase 3 interim readouts, and alvelestat Phase 3 initiation. Average price target: $7.50
Financial Runway
With $48.7M cash balance, Mereo is funded into 2026, excluding potential partnerships. Analysts project $750M+ revenue opportunity for setrusuma
Rare Disease Pionee
Mereo Biopharma's setrusumab and alvelestat show promise in addressing unmet needs in osteogenesis imperfecta and AATD-associated lung disease
Read full SWOT analysis

Compare MREO to Peers and Sector

Metrics to compare
MREO
Peers
Sector
Relationship
P/E Ratio
−13.7x−5.6x−0.7x
PEG Ratio
0.48−0.260.00
Price / Book
8.6x1.9x2.6x
Price / LTM Sales
620.5x17.6x3.2x
Upside (Analyst Target)
72.1%106.1%46.5%
Fair Value Upside
Unlock25.0%9.3%Unlock

Analysts' Recommendations

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 7.077

(+85.74% Upside)

People Also Watch

35.370
VRNA
-4.22%
17.370
ZETA
-2.20%
15.000
WVE
-4.40%
23.96
TTMI
-1.20%
15.36
MIR
+2.13%

FAQ

What Is the Mereo BioPharma ADR (MREO) Stock Price Today?

The Mereo BioPharma ADR stock price today is 3.81

What Stock Exchange Does Mereo BioPharma ADR Trade On?

Mereo BioPharma ADR is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Mereo BioPharma ADR?

The stock symbol for Mereo BioPharma ADR is "MREO."

What Is the Mereo BioPharma ADR Market Cap?

As of today, Mereo BioPharma ADR market cap is 622.10M.

What is Mereo BioPharma ADR Earnings Per Share?

The Mereo BioPharma ADR EPS is -0.314.

What Is the Next Mereo BioPharma ADR Earnings Date?

Mereo BioPharma ADR will release its next earnings report on Mar 26, 2025.

From a Technical Analysis Perspective, Is MREO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.